NeuroSense expands Alzheimer’s IP with U.S. patent, but all eyes are on RoAD trial results
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.